Hi guys, I'm currently not in ACR but in a Canadian company called Trimel. They are developing an intra nasal TRT product called Compleo and they have their PDUFA date May 28th. Is that product something you guys have been talking about and do you still see Axiron as superior ? No doubt that Axiron is the best product on the US market today but I think an intra nasal administration is very interesting regarding the reduced risk of transferral and because if the lower dose. However, you are already on the market and you have Lily. I'm wondering if I should hedge a little with a core position in ACR. Best, J
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.8¢ |
Change
-0.001(5.26%) |
Mkt cap ! $7.339M | |||
| Open | High | Low | Value | Volume |
| 1.9¢ | 1.9¢ | 1.8¢ | $11.58K | 619.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 335415 | 1.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.9¢ | 516258 | 1 |
View Market Depth
| Last trade - 16.10pm 23/06/2025 (20 minute delay) ? |
| ACR (ASX) Chart |